SOURCE: Arrayit Corporation

Arrayit Corporation

February 18, 2010 07:00 ET

Arrayit Corporation Has Discovered a Pathway to True Health Care Reform With Pre-symptomatic Diagnostics

Proteomic Biomarkers From a Patient's Immune System Give Doctors and Patients a Fighting Chance

SUNNYVALE, CA--(Marketwire - February 18, 2010) - Arrayit Corporation (OTCBB: ARYC), a leading manufacturer of products and services for disease prevention, treatment and cure, announces that the company's new proteomic biomarkers are leading the way to true pre-symptomatic diagnosis of a variety of debilitating and fatal diseases including ovarian cancer, prostate cancer and Parkinson's Disease.

Arrayit's recent discovery of proteomic biomarkers for ovarian cancer provides a roadmap for the design of new tests that can detect the presence of specific cancers and diseases long before they have become symptomatic. Unlike biomarkers that are produced by tumors and full blown disease symptoms, Arrayit's proteomic platform leverages a patient's immune response to a specific disease state, allowing doctors to get an early jump on the disease.

Arrayit President Dr. Mark Schena had this to say: "Proteomic biomarkers from a patient's immune response provide molecular beacons that enable doctors and clinicians to determine the presence of a disease well ahead of full blown deadly symptoms. Pre-symptomatic diagnosis affords doctors greater treatment options and patients a fighting chance for recovery. The larger picture of this effort is reduced health care costs through disease prevention and personalized medicine."

Arrayit, in collaboration with several of the nation's leading research centers, is developing proteomic tests for a number of diseases to affect a paradigm shift in health care.

About Arrayit

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Arrayit now offers over 650 products to a customer base of more than 10,000 clinics and research facilities, and more than 5,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit for more information.

Safe Harbor Statement

We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009, Form 10-Q/A for the fiscal second quarter ended June 30, 2009 and Form 10-Q for the fiscal third quarter ended September 30, 2009.

Contact Information